TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00724373

Intervention type: BIOLOGICAL
Intervention: Peginterferon alfa-2b (SCH 54031)
Description: Peginterferon alfa-2b plus ribavirin will be administered according to the products' labeling.

Intervention type: DRUG
Intervention: Ribavirin (SCH 18908)
Description: Peginterferon alfa-2b plus ribavirin will be administered according to the products' labeling.
Study: NCT02698865

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MONOVISC
Description: Two (2) intra-articular injections of 4 ml MONOVISC, separated by 1 month, delivered under image guidance (ultrasound or fluoroscopy)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Two (2) intra-articular injections of 4 ml saline, separated by 1 month, delivered under image guidance (ultrasound or fluoroscopy)
Study: NCT02940730

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalbavancin via Intravenous Administration
Description: Patients will undergo plasma fluid pharmacokinetic sampling for determination of dalbavancin concentrations at time zero, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, at time of volume exchange.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalbavancin via Intraperitoneal Administration
Description: Patients will undergo peritoneal fluid pharmacokinetic sampling for determination of dalbavancin concentrations at time zero, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, at time of volume exchange.
Study: NCT03527251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Patients received two doses of intravenous ipilimumab (at a dose of 1 mg per kilogram of body weight) every 3 weeks, following by intravenous SHR-1210 (at a fixed dose of 200mg) every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: Patients received two doses of intravenous ipilimumab (at a dose of 1 mg per kilogram of body weight) every 3 weeks, following by intravenous SHR-1210 (at a fixed dose of 200mg) every 2 weeks.
Study: NCT00375492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection, 5mcg or 10mcg, twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous injection, volume equivalent to exenatide dose, twice a day
Study: NCT02474147

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Processed meat hamburger
Description: MacMuffin Fresh 300 ml Cafe Latte + 21 g sugar Energy: 513.6 kcal Carbohydrates 55g (44.8%) Proteins 20.5g (16.7%) Lipids 22 g (38.6%)
Study: NCT01287299

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Glycemic Load diet
Description: Pregnant women were counseled to consume a diet with a glycemic load per 1000 kcal of less than 55.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Fat Diet
Description: Pregnant women were counseled to consume diets providing less than 25% of the energy as fat.
Study: NCT00916227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-614, p38/Tie2 inhibitor; oral
Description: Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
Study: NCT02725463

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Labyrinth Devices MVI™ Multichannel Vestibular Implant
Study: NCT04544280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeomin Injectable Product
Description: Intramuscular injection
Study: NCT01570387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Cohort 1 = 2 mg/day, Cohort 2 = 3 mg/day, Cohort 3 = 4 mg/day: Days 1-21 of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Cohort 1 = 2 mg/day, Cohort 2 = 3 mg/day, Cohort 3 = 4 mg/day: Days 1-21 of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Cohort 1 = 2 mg/day, Cohort 2 = 3 mg/day, Cohort 3 = 4 mg/day: Days 1-21 of a 28 day cycle
Study: NCT02474147

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Processed meat hamburger
Description: MacMuffin Fresh 300 ml Cafe Latte + 21 g sugar Energy: 513.6 kcal Carbohydrates 55g (44.8%) Proteins 20.5g (16.7%) Lipids 22 g (38.6%)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Processed meat hamburger
Description: MacMuffin Fresh 300 ml Cafe Latte + 21 g sugar Energy: 513.6 kcal Carbohydrates 55g (44.8%) Proteins 20.5g (16.7%) Lipids 22 g (38.6%)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vegan sandwich
Description: Burger with tofu + 300 ml green tea Energy 514.9 kcal Carbohydrates 54.2 g (44%) Proteins 19.9 g (16.2%) Lipids 22.8 g (39.8%)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vegan sandwich
Description: Burger with tofu + 300 ml green tea Energy 514.9 kcal Carbohydrates 54.2 g (44%) Proteins 19.9 g (16.2%) Lipids 22.8 g (39.8%)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vegan sandwich
Description: Burger with tofu + 300 ml green tea Energy 514.9 kcal Carbohydrates 54.2 g (44%) Proteins 19.9 g (16.2%) Lipids 22.8 g (39.8%)
Study: NCT00740415

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Rituximab, 375 mg/m2 Intraveinous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: -Velcade®, 1,3 mg/m2 Intraveinous on days 1, 4, 8 and 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: day - Dexamethasone, 40 mg Intraveinous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: -Day 1 and day 2 Bendamustine/Levact ®,, 90 mg/m2 Intraveinous
Study: NCT03861741

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: WES
Description: A peripheral venous blood sample will be processed internally, and externally subjected to WES. Only genetic material from relatives of probands in which a mutation has been identified will be sequenced.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: A MRI of the thoracic aorta will be performed in all relatives able to attend the Glenfield Hospital and who have no contra-indications to this imaging modality; pulse-wave velocity will be recorded.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TTE
Description: TTE screening will be performed by a trained physiologist. Aortic diameter will be measured from the parasternal long-axis view at the sinuses of Valsalva and at the widest level of the ascending aorta. All measurements will be made in end-diastole.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Acceptability questionnaires will be submitted to assess a baseline score of depression/anxiety that will be compared with a follow up value at three months
Study: NCT04775290

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga lessons
Description: 2 weekly yoga classes during the 5 weeks of radiotherapy
Study: NCT00484614

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Mammography
Description: Molecular Imaging Device

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Imaging Device
Study: NCT02042898

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive Transfusion Strategy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liberal transfusion strategy
Study: NCT02675309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Study: NCT04962282

Intervention type: OTHER
Intervention: Follow-up by telephone
Description: Studies have shown that the compliance of patients at 8-12 weeks reaches a peak, so this time node is the most suitable time node to investigate compliance. Telephone follow-up is irreplaceable convenience, so the telephone follow-up survey of patient compliance with exercise prescriptions is The most feasible method The purpose of the telephone follow-up is to 1. Investigate the compliance of the patients; 2. Make the patients fill out a self-made research compliance scale influencing factors through the telephone.The purpose of the telephone follow-up is to 1. Investigate the compliance of the patients; 2. Make the patients fill out a self-made research compliance scale influencing factors through the telephone.
Study: NCT01012453

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: A randomised clinical trial of the effect of classification and individual counselling
Description: The trial to be conducted is a randomised single-blinded parallel study. It is divided in two stages, T = 0 and follow-up at T = 6 months. All included participants will have a clinical examination at the beginning and at follow-up in the trial. Half of the participants will be randomised to intervention, the other half to control. The participants in the intervention group will, after the first clinical examination, pass on directly to the intervention which includes an allergological examination (patch and prick testing). Three days later they will be examined by a physician who will interpret the patch test and give a thorough, individual guidance in skin protection and occupational safety. The clinical examination of all participants at follow-up will reveal the difference in outcomes in the intervention and the control group.
Study: NCT01495936

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RM + Positive End Expiratory Pressure
Description: A recruitment maneuver (RM) will be applied to the ventilated lung by performing a valsalva maneuver for 5 seconds (holding the inspiratory pressure at 25cmH2O). Immediately after the RM, Positive End Expiratory Pressure (PEEP) will be applied to the ventilated lung at a pressure of 5cmH2O for 20 minutes. Both the RM and PEEP will be performed using the operating room ventilator.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure
Description: Continuous positive airway pressure, at a pressure of 5cmH2O will applied to the non-ventilated lung for 20 minutes by the Mallinckrodt Bronchocath Disposable CPAP system (a recognised anesthetic breathing system design for CPAP)
Study: NCT01701453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)
Description: P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)
Description: P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)
Study: NCT05223205

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Air
Description: Test if air is sufficient for macular hole closure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 10% SF6 and 90% air
Description: Test if 10% SF6 and 90% air is sufficient for macular hole closure.
Study: NCT01126112

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab: 6 mg/Kg Q2W
Study: NCT01086917

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: each volunteer to receive a single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: each volunteer to receive a single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: each volunteer to receive a single dose
Study: NCT00366873

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Calcium absorption
Description: formula with or without prebiotics

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Calcium absorption
Description: formula with or without prebiotics
Study: NCT03185819

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Placebo
Description: Participants will receive placebo as intranasal dose to match intranasal esketamine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam Placebo Solution
Description: Participants will receive placebo as oral dose to match midazolam drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam Placebo Solution
Description: Participants will receive placebo as oral dose to match midazolam drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam Placebo Solution
Description: Participants will receive placebo as oral dose to match midazolam drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Participants will receive midazolam solution 0.125 mg/kg as oral dose to match placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Participants will receive esketamine at a dose of 28 mg as intranasal solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Participants will receive esketamine at a dose of 56 mg as intranasal solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Participants will receive esketamine at a dose of 84 mg as intranasal solution.
Study: NCT01328418

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lengthening over nail
Description: External fixator is used to lengthen either the femur or the tibia over an intramedullary nail
Study: NCT02712658

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbutaline
Description: K+ transport and Ca2+ release and uptake function are stimulated by administration of terbutaline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02704741

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2RE
Description: The CO2RE system device is intended for dermatological procedures requiring ablation, coagulation and resurfacing of soft tissue, including skin
Study: NCT02890368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTI-621 Monotherapy
Description: TTI-621 (SIRPα-IgG1 Fc) is a soluble recombinant fusion protein created by directly linking the sequences encoding the N-terminal CD47 binding domain of human SIRPα with the Fc domain of human immunoglobulin (IgG1). TTI-621 acts by binding human CD47 and preventing it from delivering an inhibitory do not eat (antiphagocytic) signal to macrophages.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTI-621 Monotherapy
Description: TTI-621 (SIRPα-IgG1 Fc) is a soluble recombinant fusion protein created by directly linking the sequences encoding the N-terminal CD47 binding domain of human SIRPα with the Fc domain of human immunoglobulin (IgG1). TTI-621 acts by binding human CD47 and preventing it from delivering an inhibitory do not eat (antiphagocytic) signal to macrophages.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTI-621 Monotherapy
Description: TTI-621 (SIRPα-IgG1 Fc) is a soluble recombinant fusion protein created by directly linking the sequences encoding the N-terminal CD47 binding domain of human SIRPα with the Fc domain of human immunoglobulin (IgG1). TTI-621 acts by binding human CD47 and preventing it from delivering an inhibitory do not eat (antiphagocytic) signal to macrophages.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTI-621 + PD-1/PD-L1 Inhibitor
Description: TTI-621 will be given in combination with one of the following programmed death-1 (PD-1) or programmed death-ligand-1 (PD-L1) inhibitors: nivolumab, pembrolizumab, durvalumab, avelumab, or atezolizumab administered on Day 1. Subjects in this cohort must have a cancer diagnosis for which a PD-1/PD-L1 inhibitor is approved by the FDA or listed in the National Comprehensive Cancer Network (NCCN) Guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTI-621 + pegylated interferon-α2a
Description: TTI-621 will be given in combination with pegylated interferon-α2a. Subjects in this cohort must have a cancer diagnosis for which pegylated interferon-α2a is approved by the FDA or listed in the National Comprehensive Cancer Network (NCCN) Guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TTI-621 + T-Vec
Description: TTI-621 will be given in combination with talimogene laherparepvec (T-Vec). Subjects in this cohort must have unresectable melanoma.
Study: NCT02791087

Intervention type: OTHER
Intervention: Intra-operative graft flow rate measurement
Description: This procedure involves the insertion of a Medistim Ultrasound Transit Time Flow Probe into the graft vessel to measure its flow rate. This technique is commonly used for evaluating graft opening during CABG surgery.
Study: NCT02890368

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TTI-621 + radiation
Description: TTI-621 will be given following radiation to the target plasmacytoma. Subjects in this cohort must have relapsed multiple myeloma with bony or soft tissue plasmacytoma(s).
Study: NCT02599142

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group A: Closed-face shell
Description: As for arm description

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group B: Open-face shell
Description: As for arm description
Study: NCT02427633

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention UKRC 1997
Description: Educational poster intervention indicating the modified UKRC 1997 recovery position

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention UKRC 2010
Description: Educational poster intervention indicating the modified UKRC 2010 recovery position
Study: NCT04566458

Intervention type: OTHER
Intervention: No intervention
Description: retrospective chart review study
Study: NCT04562636

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Environmental message
Description: Participants will be randomized to view a set of four messages about the environmental harms of meat production from the Meatless Monday campaign.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health message
Description: Participants will be randomized to view a set of four messages about the health harms of meat consumption from the Meatless Monday campaign.

Intervention type: OTHER
Group type: OTHER
Intervention: Neutral Message
Description: Participants will be randomized to view a set of four messages about checking their credit score.
Study: NCT03623997

Intervention type: OTHER
Intervention: Iron stable isotope labeled iron(II) sulfate
Description: Administration of oral stable isotope labels using different dosings and different regimens in women with iron deficiency anemia
Study: NCT03020745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3389404
Description: GSK3389404 is available as Clear colorless to slightly yellow solution for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3389404
Description: GSK3389404 is available as Clear colorless to slightly yellow solution for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3389404
Description: GSK3389404 is available as Clear colorless to slightly yellow solution for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3389404
Description: GSK3389404 is available as Clear colorless to slightly yellow solution for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3389404
Description: GSK3389404 is available as Clear colorless to slightly yellow solution for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3389404
Description: GSK3389404 is available as Clear colorless to slightly yellow solution for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is available as a Clear colorless solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is available as a Clear colorless solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is available as a Clear colorless solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is available as a Clear colorless solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is available as a Clear colorless solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is available as a Clear colorless solution.
Study: NCT00657943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: metformin tablets 2 g x 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: metformin tablets 2 g x 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: metformin tablets 2 g x 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: insulin as requested
Study: NCT00305851

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Undergo therapeutic music video therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial Assessment and Care
Description: Undergo books on tape therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Psychosocial Assessment and Care
Description: Undergo books on tape therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT04190953

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Twin block then Hyrax
Description: Patients will undergo mandibular advancement prior to maxillary expansion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyrax then Twin block
Description: Patients will undergo maxillary expansion prior to mandibular advancement
Study: NCT02875821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipragliflozin
Description: Patients treated with ipragliflozin (50 mg/day) as add on therapy to metformin and pioglitazone dual therapy (triple therapy) for 6 months. During whole periods of study, subjects are educated for nutrition and exercise. (Experimental Group)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin with pioglitazone
Description: Patients maintain metformin and pioglitazone dual therapy for 6 months. During whole periods of study, subjects are educated for nutrition and exercise. (Control group)
Study: NCT01253421

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amisulpride
Description: single low-dose pharmacological challenge, 50 mg amisulpride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amisulpride
Description: single low-dose pharmacological challenge, 50 mg amisulpride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single-dose placebo capsule